MGI PHARMA to Present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN) today announced that Lonnie Moulder, President and Chief Executive Officer of MGI PHARMA, will present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York City on Thursday, February 8, 2007 at 10:20 a.m. Eastern Time. Mr. Moulder will provide an overview of the Company, its products, pipeline and 2007 corporate goals.
The presentation will be webcast live and may be accessed by logging on to MGI PHARMAs corporate website at www.mgipharma.com. Please connect to the Companys website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. An archived version of the presentation will be available through February 15, 2007.
About MGI PHARMA
MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA has a portfolio of proprietary pharmaceuticals, and intends to become a leading biopharmaceutical company. MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets.
